Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors

<p>Glioblastoma patient characteristics (DFCI)</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Joseph Toker (15399882) (author)
Andere auteurs:	J. Bryan Iorgulescu (15030477) (author), Alexander L. Ling (15399885) (author), Genaro R. Villa (15399888) (author), Josephina A.M.A. Gadet (15399891) (author), Laxmi Parida (15112564) (author), Gad Getz (14945542) (author), Catherine J. Wu (14944480) (author), David A. Reardon (15043854) (author), E. Antonio Chiocca (15399894) (author), Marco Mineo (15399897) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Cancer Detection and Diagnosis Immuno-oncology Biomarkers CNS Cancers Gliomas, Glioblastomas Immunotherapy Checkpoint blockade Skin Cancers Melanoma
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
door: Isha Mondal (16721699)
Gepubliceerd in: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
door: Francesca Orzan (15055579)
Gepubliceerd in: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
door: Francesca Orzan (15055579)
Gepubliceerd in: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
door: Francesca Orzan (15055579)
Gepubliceerd in: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
door: Michael Kilian (16697663)
Gepubliceerd in: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
door: Michael Kilian (16697663)
Gepubliceerd in: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
door: Michael Kilian (16697663)
Gepubliceerd in: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
door: Sied Kebir (15048732)
Gepubliceerd in: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
door: Sied Kebir (15048732)
Gepubliceerd in: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
door: Sied Kebir (15048732)
Gepubliceerd in: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
door: Sied Kebir (15048732)
Gepubliceerd in: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
door: Sied Kebir (15048732)
Gepubliceerd in: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
door: Defne Bayik (14961098)
Gepubliceerd in: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
door: Qingsheng Xu (17078830)
Gepubliceerd in: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
door: Qingsheng Xu (17078830)
Gepubliceerd in: (2025)

Graphical abstract from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
door: Reza Mirzaei (15306062)
Gepubliceerd in: (2025)

Supplementary Table S1 from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
door: Reza Mirzaei (15306062)
Gepubliceerd in: (2025)

Supplementary Table S2 from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
door: Reza Mirzaei (15306062)
Gepubliceerd in: (2025)

Figures 1 from Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma
door: Bachchu Lal (17141949)
Gepubliceerd in: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
door: William Kelly (15439117)
Gepubliceerd in: (2025)

Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
door: William Kelly (15439117)
Gepubliceerd in: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
door: Anne-Florence Blandin (15056366)
Gepubliceerd in: (2025)

Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
door: Tobias Kessler (17079209)
Gepubliceerd in: (2025)

Supplementary Figure S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
door: Tobias Kessler (17079209)
Gepubliceerd in: (2025)

Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
door: Tobias Kessler (17079209)
Gepubliceerd in: (2025)

Supplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
door: Tobias Kessler (17079209)
Gepubliceerd in: (2025)

Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
door: Tobias Kessler (17079209)
Gepubliceerd in: (2025)

Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
door: Tobias Kessler (17079209)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_qdmntp3rq99et8uucas7auo8rf